MedTrace Logo

Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis

NCT03243864 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2019-04-10

No results posted yet for this study

Summary

The study's primary objective is to determine plasma and dialysis fluid concentrations in patients prescribed ceftazidime-avibactam as the standard treatment for their infection and requiring continuous venovenous hemodiafiltration (CVVHDF) as part of the standard treatment for acute or chronic renal failure. Secondarily, the study will evaluate the pharmacokinetics of ceftazidime-avibactam in these patients on CVVHDF. The study will also determine if the prescribed dose meets pharmacodynamic targets.

Conditions

Interventions

DRUG

Ceftazidime-avibactam

Patients will be started on 2.5 gm IV every 8 hours

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Temple University

    lead OTHER

Principal Investigators

  • Christina Rose, Pharm.D. · Temple University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-13
Primary Completion
2020-03-21
Completion
2020-10-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03243864 on ClinicalTrials.gov